文献速递甲状腺疾病

左甲状腺素联合碘塞罗宁与左甲状腺素联合安慰剂对无甲状腺低危甲状腺癌患者心血管代谢影响的双盲随机对照试验初步结果

Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients.
PubMed 文献 · Thyroid · 2023-10-23

一项双盲随机对照试验纳入38例无心血管危险因素的无甲状腺低危甲状腺癌患者,随机接受左甲状腺素联合碘塞罗宁或左甲状腺素联合安慰剂治疗,24例完成1年评估。联合治疗组舒张功能改善,E/e'比值显著降低(p=0.046),未发生心动过速、心律失常、心房颤动等不良事件。

要点

  • 左甲状腺素联合碘塞罗宁治疗1年可改善无甲状腺低危甲状腺癌患者舒张功能,E/e'比值显著降低(p=0.046)。
  • 联合治疗组游离三碘甲状腺原氨酸水平与E/e'比值变化量呈显著相关(标准化β=0.603,p=0.050)。
  • 研究期间未发生心动过速、心律失常、心房颤动或其他重要不良事件。

核心结论

  • 在此初步报告中,左甲状腺素联合碘塞罗宁治疗对舒张功能的心血管参数产生有利变化,且未发生任何心血管不良事件。

研究设计与样本

  • 随机、双盲、安慰剂对照研究,从300例常规随访的低危甲状腺癌患者中选取38例符合纳入标准的术后甲状腺功能减退患者,随机接受左甲状腺素联合碘塞罗宁或左甲状腺素联合安慰剂治疗。
  • 24例患者在治疗1年后完成评估,所有临床和实验室参数与50名性别、年龄、体力活动和生活方式匹配的健康甲状腺功能正常志愿者进行比较。
  • 参与者和临床医生对治疗分配保持盲态。

主要发现

  • 治疗1年后,左甲状腺素联合碘塞罗宁组较左甲状腺素联合安慰剂组E/e'比值显著降低(p=0.046),舒张功能改善,且E/e'比值随时间呈正向趋势。
  • 单变量分析显示,联合治疗后左甲状腺素联合碘塞罗宁组游离三碘甲状腺原氨酸水平(单位pg/mL)与E/e'比值变化量Δ呈显著相关(标准化β系数=0.603[置信区间:0.001-1.248],p=0.050)。
  • 从首次给药至研究结束,未发生心动过速、心律失常、心房颤动或其他重要不良事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Evidence is needed on the risks and benefits of combination therapy with levothyroxine (LT4)+liothyronine (LT3) for the treatment of hypothyroidism. Objective and Methods: We performed a randomized, double-blind placebo-controlled study to assess the effects of LT4+LT3 therapy versus LT4+placebo in a homogeneous group of athyreotic patients, without cardiovascular risk factors during long-term replacement monotherapy with LT4. The primary objective of the study was to assess the effects of combination LT4+LT3 therapy on heart rate, cardiac rhythm, and sensitive cardiovascular parameters of cardiac morphology and function by means of electrocardiography and Doppler echocardiography. The secondary objective of the study was to evaluate patient compliance, tolerability, and potential adverse events. Results: Thirty-eight patients with postsurgical hypothyroidism satisfying the inclusion criteria were selected from a group of 300 patients with low-risk thyroid cancer followed for a routine follow-up; they were randomized to receive LT4+LT3 or LT4+placebo. Twenty-four patients were evaluated after 1 year of treatment. All clinical and laboratory parameters were compared with the results obtained from 50 healthy euthyroid volunteers without comorbidities, matched for gender, age, physical activity, and lifestyle. Participants and clinicians remained blinded to the treatment allocation. After 1 year of combination therapy, a significant improvement in the diastolic function, evidenced by a significant reduction in the E/e' ratio (p = 0.046) and its positive trend over time, was observed in the LT4+LT3 group versus the LT4+placebo group. In addition, the univariate analyses showed a significant relationship between free triiodothyronine (fT3) levels (in pg/mL) with Δ of variation of the E/e' ratio in the LT4+LT3 group (standardized β coefficient = 0.603 [confidence interval: 0.001-1.248], p = 0.050) after combination therapy. No adverse events including tachycardia, arrhythmias, atrial fibrillation, or other important events occurred between the first administration and the end of the study. Conclusions: In this preliminary report, combination treatment with LT4+LT3 induced favorable changes in cardiovascular parameters of diastolic function without any adverse cardiovascular events. Trial Registration: EUDRACT number: 2017-001261-25.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Biondi B, Pucci M, Pontieri G, et al. Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients. Thyroid. 2023. PMID: 37725587. doi:10.1089/thy.2023.0135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。